Page 5 - தகவல்தொடர்புகள் முதலீட்டாளர் உறவுகள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

22nd Century Group Provides Business Update from CEO Detailing Company Progress Over Past Year

22nd Century Group Provides Business Update from CEO Detailing Company Progress Over Past Year
apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.

United statesNeedle rockMei kuoJamesa mishCentury group incCommunications investor relationsCentury groupDrug administrationCompany annual report on formSales of companyFellow shareholdersModified risk tobacco productLess nicotineMenthol kingNeedle rock farmsCentury canada

VEON Makes AdTech Acquisition In Russia

VEON Makes AdTech Acquisition In Russia
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

Noord hollandNik kershawKaan terziogluCommunications investor relationsUs securities exchangeBusiness developmentEuronext amsterdamRussian adtechBeeline russiaExecutive vice presidentNew business developmentBig dataEuronext amsterdam listedExchange actநூற்த் ஹாலண்ட்நிக் கெர்ஷா

Investegate |Frontier IP Group Announcements | Frontier IP Group: Publication of newsletter

Investegate announcements from Frontier IP Group, Publication of newsletter

Nick athanas george payneAndrew johnsonNeil crabbAllenby capital limited nominated adviserCommunications investor relationsFrontier ip group plcCapital limitedNominated adviserMarket abuse regulationInvestegate announcementsInvestegate company announcementsFrontier ip groupEgulatory news serviceEgulatory news service and regulatoryநிக் அதனாஸ் ஜார்ஜ் பேந்ஆண்ட்ரூ ஜான்சன்

CBMG Holdings Novel Anti-CD20 CAR-T Cell Therapy Shows Promising Safety and Efficacy in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma Patients Following Relapse to an anti-CD19 CAR-T Therapy

Share this article Share this article HONG KONG, June 10, 2021 /PRNewswire/ CBMG Holdings (or the Company ), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today announced early promising safety and efficacy results of C-CAR066, a novel second generation chimeric antigen receptor T (CAR-T) therapy targeting CD20 antigen in relapsed/refractory B-cell non-Hodgkin lymphoma (r/r B-NHL) that has failed to an anti-CD19 CAR-T therapy. Patients who fail anti-CD19 CAR-T therapy generally have a dismal prognosis and are an important group with high unmet medical needs. This abstract was recently presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting by the Principal Investigator (PI) of the study, Aibin Liang, M.D., Professor of Department of Hematology, Shanghai Tongji Hospital, Tongji University School of Medicine, China.

United statesTony bizuo liuAibin liangSarah kellyCommunications investor relationsAmerican society of clinical oncologyInstitute of hematology blood diseases hospitalCompany contactProfessor of department hematologyTongji university school of medicineClinical oncologyAnnual meetingPrincipal investigatorShanghai tongji hospitalTongji university schoolBlood diseases hospital

CBMG Holdings Novel CD19/CD20 Bi-specific CAR-T Cell Product Shows Early Promising Clinical Efficacy and Favorable Safety Profile in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Share this article Share this article HONG KONG, June 10, 2021 /PRNewswire/ CBMG Holdings (or the Company ), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today announced updated clinical data for C-CAR039, a novel CD19/CD20 bi-specific CAR-T cell product in relapsed or refractory (r/r) B-cell non-Hodgkin lymphoma (B-NHL). This work was presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, by the Principal Investigator (PI) of the study, Aibin Liang, M.D., Professor of Department of Hematology, Shanghai Tongji Hospital, Tongji University School of Medicine. Additionally, the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development has granted the Company an orphan drug designation (ODD) to C-CAR039, for the treatment of follicular lymphoma, an indolent form of Non-Hodgkin s Lymphoma.

United statesTony bizuo liuAibin liangKaplan meyerSarah kellyCommunications investor relationsAmerican society of clinical oncologyCompany contactDrug administrationTongji university school of medicineProfessor of department hematologyOffice of orphan products developmentClinical oncologyAnnual meetingPrincipal investigatorShanghai tongji hospital